51 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
in connection with the 2024 Private Placement
PREA
Pediatric Research Equity Act
ptau181
plasma phosphorylated tau at position 181
RA
rheumatoid arthritis
R&D
research … is believed by the Company to be of limited value. Due to its reliance on third parties in various aspects of its business, including CMC, R&D
8-K
EX-99.1
CRVO
CervoMed Inc
15 May 24
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5:06pm
to approximately $1.4 million for the same period in 2023.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were approximately
8-K
EX-99.1
bbxs8mnrslac8jkz
5 Apr 24
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
6tq5 0p7kh
13 Nov 23
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
4:06pm
8-K/A
EX-99.1
3bwbv
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
p9d4t
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
424B3
l3964chuc3hc4dffh7
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
jh6126b2oafs
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
h3v8j5p78cpu
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-2.1
h77e1 7neny
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-2.1
ryj5v
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFC14A
b5a 72cy7mz00q6of
5 Dec 22
Proxy in contested solicitation
5:12pm